Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 11/20 | 0.75 |
| ▸ | TACR1 | P25103 | 12/20 | 0.42 |
| ▸ | TACR2 | P21452 | 5/20 | 0.42 |
| ▸ | CCR5 | P51681 | 2/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12906931 | 1.00 | TACR3 (0.75) | TACR3TACR1TACR2CCR5HTR2A | |
| SCHEMBL297026 | 1.00 | TACR3 (0.75) | TACR3TACR1TACR2CCR5HTR2A | |
| SCHEMBL296583 | 0.93 | TACR3 (0.66) | TACR3TACR1TACR2CCR5HTR2A | |
| SCHEMBL12906935 | 0.93 | TACR3 (0.66) | TACR3TACR1TACR2CCR5HTR2A | |
| SCHEMBL297644 | 0.93 | TACR3 (0.65) | TACR3TACR1TACR2 | |
| SCHEMBL296724 | 0.93 | TACR3 (0.65) | TACR3TACR1TACR2 | |
| SCHEMBL297436 | 0.87 | TACR3 (0.81) | TACR3TACR1TACR2CCR5HTR2A | |
| SCHEMBL12906866 | 0.87 | TACR3 (0.81) | TACR3TACR1TACR2CCR5 | |
| SCHEMBL12906870 | 0.87 | TACR3 (0.81) | TACR3TACR1TACR2CCR5HTR2A | |
| SCHEMBL12906871 | 0.87 | TACR3 (0.81) | TACR3TACR1TACR2CCR5HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2200982-B1 | PIPERIDINE DERIVATIVES AS NK3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | KNUST HENNER | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021565-A1 | PIPERIDINE DERIVATIVES AS NK3 ANTAGONISTS | DRD2, DRD3, OPRL1 | TACR3 95/4885TACR1 26/4885TACR2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.